In a real-world cohort from primary care/endocrinology clinics, the prevalence of MASLD increased in a stepwise manner with glycaemic and BMI categories, but the prevalence of fibrosis did not increase in the same stepwise manner and remained rare in the absence of obesity, or in obesity without significant insulin resistance.
OBJECTIVES
Current metabolic dysfunction-associated steatotic liver disease (MASLD) guidelines recommend fibrosis screening in individuals with type 2 diabetes (T2D) because of their increased risk of clinically significant fibrosis (≥F2). However, fibrosis risk is variable, and clinical tools to identify individuals a...
N. Cuervo-Pardo, S. Kalavalapalli, Eddison Godinez Leiva et al.· Endocrine Practice· 0 citations
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in type 1 diabetes (T1D), yet its relationship with dynamic glycemic abnormalities and the metabolic pathways underlying these associations remains incompletely understood. We investigated the associations of hepatic...
Shuang Li, Pan-Zun Wang, Zhi-Hong Cai et al.· Frontiers in Medicine· 0 citations
Roughly 90% of patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) have at least one feature of metabolic syndrome, a disease characterized by insulin resistance, obesity, hypertension and hyperlipidemia. MASLD can be accessed by the Enhanced Liver Fibrosis test (ELF, Siemens Healthinee...
C. Orahoske, Shirley Li, Alan H. B. Wu· Clinical Chemistry· 0 citations
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non- alcoholic fatty liver disease (NAFLD), is a prevalent liver condition characterized by excessive fat accumulation in hepatocytes, primarily due to metabolic risk factors. Steatosis, the initial accumulation of fat, can p...
Pragya Goswami, S. Ray, Abhishek Singhai et al.· Journal of the National Medi...· 0 citations
Lean MASLD shared a broadly similar cardiometabolic risk structure with Obese MASLD, whereas the relative contribution of risk factors differed between phenotypes, providing exploratory evidence of phenotype-specific metabolic associations requiring validation before clinical application.
H. Kawamura, Kei Fujiwara, Ryo Sato et al.· Hepatology Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.